Drug AMG 410 for metastatic tumors with KRAS mutations (20240031)

Who Can Participate?

Age Range

18-110
Looking for Healthy Participants
No

What is Involved?

Locations

Duke University Hospital

Visit Timing

Weekdays

Compensation

No

Spanish Materials Available

No

Study Details

Full Title

[20240031] A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors

Principal Investigator

John
Strickler

Protocol Number

PRO00118236

NCT ID

NCT07094113

Phase

I

Enrollment Status

Open to Enrollment